Meet the Team

Dr. Anna Becker

co-founder and ceo

Dr. Anna Becker leads the algorithmic investments at EndoTech. She champions the AI/ML teams to capture Alpha in volatile markets. Her deep-learning algorithms managed nearly a billion dollars of investments (AuM) and have been deployed in managing institutional monies for more than a decade including work with Gilboa fund of funds. 

Before founding EndoTech, Dr. Becker founded and sold an AI company in the FinTech space (Strategy Runner sold in 2011). In 2002, as Strategy Runner CEO Dr. Becker worked with CME/CBOT, FCMs, and other participants of the Futures and Commodities eco-system, in order to promote algorithmic trading platforms to retail and institutional clients.

She has her Ph.D in artificial intelligence from Israel’s prestigious Technion University and is a published author and renowned speaker in the field of AI.

DMITRY GOOSHCHIN

CO-FOUNDER AND CHIEF OPERATING OFFICER

Dmitry is responsible for the integrated operational excellence at EndoTech.

He is a seasoned executive with 20 years’ experience scaling financial technology companies including FinTech companies namely Strategy Runner (acquired).

Dmitry holds a Master in Astrophysics and has been active in scaling algorithmic technologies for two decades. Dmitry also holds the title of “Chess Grandmaster” in correspondence chess.

ROI LEVY

CHIEF FINANCIAL OFFICER 

Over the past 22 years, Roi has provided financial and operational leadership and guidance to both large, publicly-held multinationals and mid-sized private companies.

His financial and operational leadership ensures the financial well-being of both the company and our stakeholders and customers.

Roi holds a Master in Accounting and has deep experience across both public and private companies like BAE, Siano and EY. Roi is also an avid long distance runner.

PAVEL CUNO

VP OF TECHNOLOGY

Following his Master in Computer Science, Pavel has held executive research and development roles in a host of companies ranging from young startups to publicly traded enterprises. 

He is responsible for the technological and architectural design, solution functionality and execution quality.

Pavel brings over 30 years of experience in multidisciplinary research and development to bare at EndoTech.   He has a unique combination of business, people management skills and a customer approach with a deep understanding of product and technology needs.

JAKE LEVANT

CHIEF MARKETING OFFICER 

Over the course of his 20 year career, Jake has held marketing, sales, and organizational leadership roles in high-growth, high-technology companies. Jake leads global brand and performance marketing across all lines of business and market segments.

Over the years, Jake was instrumental in scaling a number of software companies, including Answers.com (acquired), Strategy Runner (acquired), and Fring (acquired), and founded other entrepreneurial ventures. He holds an MBA from INSEAD (Fontainebleau, France) and an undergraduate degree from McGill University (Montreal, Canada).

Copyright © 2023 EndoTech.
All rights reserved.

HYPOTHETICAL PERFORMANCE RESULTS HAVE MANY INHERENT LIMITATIONS, SOME OF WHICH ARE DESCRIBED BELOW. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN; IN FACT, THERE ARE FREQUENTLY SHARP DIFFERENCES BETWEEN HYPOTHETICAL PERFORMANCE RESULTS AND THE ACTUAL RESULTS SUBSEQUENTLY ACHIEVED BY ANY PARTICULAR TRADING PROGRAM. ONE OF THE LIMITATIONS OF HYPOTHETICAL PERFORMANCE RESULTS IS THAT THEY ARE GENERALLY PREPARED WITH THE BENEFIT OF HINDSIGHT. IN ADDITION, HYPOTHETICAL TRADING DOES NOT INVOLVE FINANCIAL RISK, AND NO HYPOTHETICAL TRADING RECORD CAN COMPLETELY ACCOUNT FOR THE IMPACT OF FINANCIAL RISK OF ACTUAL TRADING. FOR EXAMPLE, THE ABILITY TO WITHSTAND LOSSES OR TO ADHERE TO A PARTICULAR TRADING PROGRAM IN SPITE OF TRADING LOSSES ARE MATERIAL POINTS WHICH CAN ALSO ADVERSELY AFFECT ACTUAL TRADING RESULTS. THERE ARE NUMEROUS OTHER FACTORS RELATED TO THE MARKETS IN GENERAL OR TO THE IMPLEMENTATION OF ANY SPECIFIC TRADING PROGRAM WHICH CANNOT BE FULLY ACCOUNTED FOR IN THE PREPARATION OF HYPOTHETICAL PERFORMANCE RESULTS AND ALL WHICH CAN ADVERSELY AFFECT TRADING RESULTS.